A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Clinical trial NCT02861014 · COMPLETED
Trial details
- NCT number
- NCT02861014
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-09
- Primary completion
- 2019-10-25
- Enrollment
- 681
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.